|
Real-time
Euronext Bruxelles
07:52:13 05/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 202.20 EUR | -1.03% |
|
-4.89% | -15.30% |
| 30/09 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 29/09 | UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session | CI |
| Market Cap | 3.9TCr 4.38TCr 3.64TCr 3.31TCr 6.25TCr 4,21500Cr 6.31TCr 44TCr 17TCr 2,15500Cr 16TCr 16TCr 6,91500Cr | P/E 2026 * |
20.4x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 3.94TCr 4.43TCr 3.67TCr 3.35TCr 6.32TCr 4,25900Cr 6.37TCr 44TCr 17TCr 2,17700Cr 17TCr 16TCr 6,98800Cr | EV / Sales 2026 * |
4.55x | EV / Sales 2027 * | 3.88x |
| Free-Float |
61.59% | Yield 2026 * |
0.71% | Yield 2027 * | 0.74% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Bruxelles
| UCB | Real-time | |
CBOE
| UCB | Real-time | |
|
Tradegate
| UNC | Real-time | |
|
Xetra
| UNC | Delayed | |
|
OTC Markets
| UCBJF | Delayed | |
|
Deutsche Boerse AG
| UNC | Delayed | |
|
London S.E.
| 0NZT | Delayed | |
|
CBOE
| 0NZT | Real-time | |
|
Wiener Boerse
| UCB | End-of-day quote | |
|
Börse Stuttgart
| UNC | Delayed | |
|
Boerse Muenchen
| UNC | Real-time | |
|
Borsa Italiana
| 4UCB | End-of-day quote |
Last Transcript: UCB
| 1 day | -0.69% | ||
| 1 week | -4.52% | ||
| Current month | -1.07% | ||
| 1 month | -3.52% | ||
| 3 months | -20.24% | ||
| 6 months | -22.97% | ||
| Current year | -14.96% |
| 1 week | 200.2 |  | 215.7 |
| 1 month | 200.2 | | 217.1 |
| Current year | 200.2 | | 289.5 |
| 1 year | 200.2 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 01/07/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/01/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/01/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/01/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.64% | -4.52% | -19.87% | +161.27% | 4.38TCr | |
| -0.61% | -3.43% | +36.07% | +115.04% | 1,01900Cr | |
| -1.02% | -5.60% | +35.72% | +64.63% | 62TCr | |
| +1.11% | -0.58% | +12.36% | +77.95% | 46TCr | |
| +0.34% | -3.01% | +61.79% | +41.24% | 36TCr | |
| +0.67% | -1.97% | +20.80% | +41.22% | 33TCr | |
| +0.79% | -3.43% | +10.81% | +34.40% | 27TCr | |
| +0.03% | -5.03% | -6.77% | +8.82% | 24TCr | |
| -1.04% | -2.79% | +35.30% | +51.84% | 22TCr | |
| -1.87% | -4.10% | +28.44% | +93.66% | 18TCr | |
| Average | -0.26% | -3.66% | +21.47% | +69.01% | 37.41TCr | |
| Weighted average by Cap. | -0.10% | -3.55% | +28.50% | +71.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 865.9Cr 974.56Cr 808.17Cr 736.62Cr 1.39TCr 94TCr 1.4TCr 9.78TCr 3.79TCr 48TCr 3.66TCr 3.58TCr 1,53700Cr | 960.66Cr 1.08TCr 896.62Cr 817.23Cr 1.54TCr 1,03900Cr 1.56TCr 11TCr 4.2TCr 53TCr 4.06TCr 3.97TCr 1,70500Cr |
| Net income | 192.8Cr 216.99Cr 179.94Cr 164.01Cr 309.33Cr 21TCr 312.21Cr 2.18TCr 843.84Cr 11TCr 814.69Cr 797.01Cr 34TCr | 229.68Cr 258.51Cr 214.37Cr 195.39Cr 368.51Cr 25TCr 371.94Cr 2.59TCr 1.01TCr 13TCr 970.56Cr 949.49Cr 41TCr |
| Net Debt | 41Cr 46Cr 39Cr 35Cr 66Cr 4.46TCr 67Cr 466.11Cr 180.62Cr 2.28TCr 174.38Cr 170.59Cr 7.33TCr | -169.5Cr -190.78Cr -158.2Cr -144.2Cr -271.96Cr -18TCr -274.49Cr -1.91TCr -741.89Cr -9.38TCr -716.27Cr -700.72Cr -30TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | €202.20 | -1.03% | 33,183 |
| 02/26/02 | €204.30 | +1.49% | 1,76,155 |
| 01/26/01 | €201.30 | -1.85% | 2,37,472 |
| 30/26/30 | €205.10 | -0.82% | 3,02,223 |
| 29/26/29 | €206.80 | -2.68% | 3,58,447 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
